NovoCure's TTFields therapy, combined with standard chemotherapy, improves overall survival in advanced pancreatic cancer.
A study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells ...
When Julie Durbin was undergoing cancer treatment, she was always cold. She would bring a cardigan, a sweater that opens in ...
Merck MRK announced that the FDA has granted breakthrough therapy designation (BTD) to sacituzumab tirumotecan (sac-TMT) for ...
A study from researchers at the University of Michigan and the University of California San Diego has shed light on a ...
In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received ...
Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...
Schad, a compassionate soul and dedicated community member, passed away on Friday, November 29, 2024, at the age of 50 at CHP ...
Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, ...
Olema Oncology has announced that it has entered into a clinical trial collaboration and supply agreement with Novartis to ...